Envafolimab and neoadjuvant chemotherapy
Phase 2Small molecule
Envafolimab and neoadjuvant chemotherapy is one of 51 small molecule programs targeting Osteosarcoma. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
50
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
135 competitors in Osteosarcoma
#DrugCompanyPhaseTrials
1Trexall
Alnylam PharmaceuticalsPhase 3
Ifex
BBaxter Healthcare Corporation
Phase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Vepesid
AAvyxa
Phase 3
Adriamycin
GGynecologic Oncology Group
Phase 3
PEG-Intron
Merck & Co.Phase 3
Adriamycin
PfizerPhase 2
Standard Chemotherapy
RochePhase 3
Cabometyx
Bristol-Myers SquibbPhase 2
Opdivo
Bristol-Myers SquibbPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Osteosarcoma1 trial
Envafolimab Combined With Neoadjuvant Chemotherapy Treat Stage IIb Resectable Osteosarcoma Patients
Not yet recruiting·SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine·Phase 2·NCT07142863·23 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details